- Home
- VYGR vs BWG Comparison
VYGR vs BWG Comparison
Compare VYGR & BWG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- BWG
- Stock Information
- Founded
- VYGR 2013
- BWG 2012
- Country
- VYGR United States
- BWG United States
- Employees
- VYGR N/A
- BWG N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- BWG Finance/Investors Services
- Sector
- VYGR Health Care
- BWG Finance
- Exchange
- VYGR Nasdaq
- BWG Nasdaq
- Market Cap
- VYGR 164.3M
- BWG 136.3M
- IPO Year
- VYGR 2015
- BWG N/A
- Fundamental
- Price
- VYGR $3.20
- BWG $8.43
- Analyst Decision
- VYGR Strong Buy
- BWG
- Analyst Count
- VYGR 8
- BWG 0
- Target Price
- VYGR $14.33
- BWG N/A
- AVG Volume (30 Days)
- VYGR 715.4K
- BWG 53.8K
- Earning Date
- VYGR 08-05-2025
- BWG 01-01-0001
- Dividend Yield
- VYGR N/A
- BWG 11.37%
- EPS Growth
- VYGR N/A
- BWG N/A
- EPS
- VYGR N/A
- BWG N/A
- Revenue
- VYGR $66,958,000.00
- BWG N/A
- Revenue This Year
- VYGR N/A
- BWG N/A
- Revenue Next Year
- VYGR $78.88
- BWG N/A
- P/E Ratio
- VYGR N/A
- BWG N/A
- Revenue Growth
- VYGR N/A
- BWG N/A
- 52 Week Low
- VYGR $2.65
- BWG $6.86
- 52 Week High
- VYGR $9.55
- BWG $8.65
- Technical
- Relative Strength Index (RSI)
- VYGR 51.88
- BWG 76.68
- Support Level
- VYGR $2.83
- BWG $8.08
- Resistance Level
- VYGR $3.43
- BWG $8.48
- Average True Range (ATR)
- VYGR 0.19
- BWG 0.09
- MACD
- VYGR 0.01
- BWG 0.03
- Stochastic Oscillator
- VYGR 55.22
- BWG 88.89
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About BWG BrandywineGLOBAL Global Income Opportunities Fund Inc.
BrandywineGLOBAL - Global Income Opportunities Fund Inc is a non-diversified, closed-end management investment company. The primary investment objective is to provide current income. The secondary investment objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing, under normal market conditions, at least 80% of its assets in world-wide fixed-income securities.